313 related articles for article (PubMed ID: 26346796)
1. Optimizing therapy early in multiple sclerosis: An evidence-based view.
Ziemssen T; De Stefano N; Sormani MP; Van Wijmeersch B; Wiendl H; Kieseier BC
Mult Scler Relat Disord; 2015 Sep; 4(5):460-469. PubMed ID: 26346796
[TBL] [Abstract][Full Text] [Related]
2. Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis.
He A; Spelman T; Jokubaitis V; Havrdova E; Horakova D; Trojano M; Lugaresi A; Izquierdo G; Grammond P; Duquette P; Girard M; Pucci E; Iuliano G; Alroughani R; Oreja-Guevara C; Fernandez-Bolaños R; Grand'Maison F; Sola P; Spitaleri D; Granella F; Terzi M; Lechner-Scott J; Van Pesch V; Hupperts R; Sánchez-Menoyo JL; Hodgkinson S; Rozsa C; Verheul F; Butzkueven H; Kalincik T;
JAMA Neurol; 2015 Apr; 72(4):405-13. PubMed ID: 25665031
[TBL] [Abstract][Full Text] [Related]
3. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies.
Wingerchuk DM; Carter JL
Mayo Clin Proc; 2014 Feb; 89(2):225-40. PubMed ID: 24485135
[TBL] [Abstract][Full Text] [Related]
4. Comparative studies of glatiramer acetate and interferon beta.
Goodin D
Int MS J; 2008 Jun; 15(2):39-41. PubMed ID: 18782497
[TBL] [Abstract][Full Text] [Related]
5. A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta.
Galassi S; Prosperini L; Logoteta A; Hirsch MN; Fanelli F; De Giglio L; Pozzilli C
Mult Scler Relat Disord; 2016 Jul; 8():99-106. PubMed ID: 27456883
[TBL] [Abstract][Full Text] [Related]
6. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.
Goodin DS; Bates D
Mult Scler; 2009 Oct; 15(10):1175-82. PubMed ID: 19737851
[TBL] [Abstract][Full Text] [Related]
7. Clinical management of multiple sclerosis: the treatment paradigm and issues of patient management.
Stuart WH
J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S19-25. PubMed ID: 15253686
[TBL] [Abstract][Full Text] [Related]
8. Optimizing treatment success in multiple sclerosis.
Ziemssen T; Derfuss T; de Stefano N; Giovannoni G; Palavra F; Tomic D; Vollmer T; Schippling S
J Neurol; 2016 Jun; 263(6):1053-65. PubMed ID: 26705122
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic approaches to disease modifying therapy for multiple sclerosis in adults: an Australian and New Zealand perspective: part 2 new and emerging therapies and their efficacy. MS Neurology Group of the Australian and New Zealand Association of Neurologists.
Broadley SA; Barnett MH; Boggild M; Brew BJ; Butzkueven H; Heard R; Hodgkinson S; Kermode AG; Lechner-Scott J; Macdonell RA; Marriott M; Mason DF; Parratt J; Reddel SW; Shaw CP; Slee M; Spies J; Taylor BV; Carroll WM; Kilpatrick TJ; King J; McCombe PA; Pollard JD; Willoughby E;
J Clin Neurosci; 2014 Nov; 21(11):1847-56. PubMed ID: 24986155
[TBL] [Abstract][Full Text] [Related]
10. Established and novel disease-modifying treatments in multiple sclerosis.
Cross AH; Naismith RT
J Intern Med; 2014 Apr; 275(4):350-63. PubMed ID: 24444048
[TBL] [Abstract][Full Text] [Related]
11. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
12. Balancing Early Aggression Against Risk of Progression in Multiple Sclerosis.
Duquette P; Giacomini PS; Bhan V; Hohol M; Schecter R
Can J Neurol Sci; 2016 Jan; 43(1):33-43. PubMed ID: 26611431
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic decision making in a new drug era in multiple sclerosis.
Keegan BM
Semin Neurol; 2013 Feb; 33(1):5-12. PubMed ID: 23709208
[TBL] [Abstract][Full Text] [Related]
14. The Relationship Between Brain MR Spectroscopy and Disability in Multiple Sclerosis: 20-Year Data from the U.S. Glatiramer Acetate Extension Study.
Khan O; Seraji-Bozorgzad N; Bao F; Razmjou S; Caon C; Santiago C; Latif Z; Aronov R; Zak I; Ashtamker N; Kolodny S; Ford C; Sidi Y
J Neuroimaging; 2017 Jan; 27(1):97-106. PubMed ID: 27214389
[TBL] [Abstract][Full Text] [Related]
15. United States open-label glatiramer acetate extension trial for relapsing multiple sclerosis: MRI and clinical correlates. Multiple Sclerosis Study Group and the MRI Analysis Center.
Wolinsky JS; Narayana PA; Johnson KP;
Mult Scler; 2001 Feb; 7(1):33-41. PubMed ID: 11321192
[TBL] [Abstract][Full Text] [Related]
16. Treatment of pediatric multiple sclerosis and variants.
Pohl D; Waubant E; Banwell B; Chabas D; Chitnis T; Weinstock-Guttman B; Tenembaum S;
Neurology; 2007 Apr; 68(16 Suppl 2):S54-65. PubMed ID: 17438239
[TBL] [Abstract][Full Text] [Related]
17. Impact of diagnosis and early treatment on the course of multiple sclerosis.
Noyes K; Weinstock-Guttman B
Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633
[TBL] [Abstract][Full Text] [Related]
18. Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.
Ehling R; Di Pauli F; Lackner P; Rainer C; Kraus V; Hegen H; Lutterotti A; Kuenz B; De Zordo T; Schocke M; Glatzl S; Löscher WN; Deisenhammer F; Reindl M; Berger T
J Neuroimmunol; 2015 Oct; 287():98-105. PubMed ID: 26439969
[TBL] [Abstract][Full Text] [Related]
19. MRI evidence for multiple sclerosis as a diffuse disease of the central nervous system.
Filippi M; Rocca MA
J Neurol; 2005 Nov; 252 Suppl 5():v16-24. PubMed ID: 16254697
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy, effects on MRI and tolerability of weekly intramuscular interferon-beta-1a in patients with MS and CIS.
Zivadinov R; Munschauer FE; Ramanathan M; Benedict RH; Weinstock-Guttman B
Drugs Today (Barc); 2008 Aug; 44(8):601-13. PubMed ID: 18846271
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
